Episodios

  • S26:E3 – Rewriting the ET Playbook
    Oct 31 2025

    In this episode, Rewriting the ET Playbook, Dr. Douglas Tremblay and Dr. Ruben Mesa review the current therapeutic options for treating essential thrombocythemia, and they review therapies on the horizon that are currently in late-stage clinical trials. What do clinicians need to know for managing this blood disorder?

    Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    25 m
  • S26:E2 – Treatment Success in PV
    Oct 31 2025

    In this episode, Treatment Success in PV, Dr. Douglas Tremblay and Dr. Ruben Mesa focus on the goals of therapy for polycythemia vera, namely improving symptom burden and reducing thrombosis.

    Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    26 m
  • S26:E1 – From Clues to Classification: PV and ET Diagnosis and Risk Stratification
    Oct 31 2025

    In this episode, From Clues to Classification, PV and ET Diagnosis Risk Stratification, Dr. Douglas Tremblay and Dr. Ruben Mesa discuss how clinicians can make an accurate diagnosis for these two blood disorders and how to prevent vascular complications, particularly how risk stratification can guide therapeutic shared decision-making.

    Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    29 m
  • S25:E2 – Managing RET Fusion-Positive NSCLC
    Jul 14 2025

    In this episode, our faculty, Dr. Justin F. Gainor and Elizabeth A. Krueger, CNP, discuss practical and evidence-based strategies for managing patients with RET fusion-positive NSCLC. Learn about the defining pathologic features that distinguish this lung cancer, the recommended testing modalities for RET fusions, treatment selection, and how to manage adverse effects.

    Visit https://suitehome.atpointofcare.com/library/2694.02/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    27 m
  • S25:E1 – ALK-Positive NSCLC: Navigating the Treatment Landscape
    Jul 14 2025

    In this episode, our faculty, Dr. Charu Aggarwal and Beth Sandy, MSN, CRNP, FAPO, discuss biomarker testing, first-line treatment decisions, including some of the latest clinical data from the anaplastic lymphoma kinase (ALK) trials, and real-world strategies to manage toxicities in patients with ALK-positive NSCLC.

    Visit https://suitehome.atpointofcare.com/library/2694.01/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    27 m
  • S24:E3 – Evidence-Based Strategies for Individualizing CAR T-Cell Therapy in Patients With RRMM
    Jun 27 2025

    In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss what clinicians need to know about optimizing treatment strategies for their patients with multiple myeloma. They explore approaches to bridging therapy to improve efficacy and reduce toxicity, evidence-based principles for sequencing B-cell maturation antigen (BCMA)-targeted agents, and how to navigate the challenge of prior BCMA exposure to improve patient outcomes. Visit https://suitehome.atpointofcare.com/library/2676.13/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    23 m
  • S24:E2 – Identifying Patients for CAR T-Cell Therapy in Earlier Treatment Lines for RRMM
    Jun 27 2025

    In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss patient selection. Who is the ideal candidate for chimeric antigen receptor (CAR) T-cell therapy? The latest evidence from ASH and Tandem meetings adds crucial data to patient selection strategies. Visit https://suitehome.atpointofcare.com/library/2676.12/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    Más Menos
    24 m
  • S24:E1 – CAR T-Cell Therapy Earlier in Treatment for RRMM
    Jun 27 2025

    In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, explore shifting CAR T-cell therapy into earlier lines of treatment for patients with relapsed/refractory disease, and discuss treatment updates recently presented at ASH 2024 and the 2025 Tandem Meetings. ** Visit https://suitehome.atpointofcare.com/library/2676.11/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit**

    Más Menos
    23 m